Merck & Co. (MRK) Stock Forecast for 2024–2028. Sell or Buy Prediction







Buy or Sell TSLA stocks? (TSLA) forecasting

Tesla: At A Crossroads

May 29, 2024
Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Merck & Co. (MRK) Stock Forecast for 2024–2028. Sell or Buy?

Updated: May 30, 2024 (16:16)

Sector: Healthcare

The share price of Merck & Co., Inc. (MRK) now

Latest session on the 30th of May for
Merck & Co., Inc. is negative
Trading Volume: 13000272
Open: 126.02 /  High: 127.85 /  Low: 122.7
What analysts predict: $142.18
52-week High/Low: $133.1 / $97.81

50/200 Day Moving Average: $128.03 / $115.54

This figure corresponds to the Average Price over the previous 50/200 days. For Merck & Co. stocks, the 50-day moving average is the resistance level today.

For Merck & Co. stocks, the 200-day moving average is the support level today.

Are you interested in Merck & Co., Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Merck & Co. stock price in 2024, 2025, 2026, 2027, 2028. How much will one Merck & Co. share be worth in 2024 - 2028?

When should I take profit in Merck & Co. stock? When should I record a loss on Merck & Co. stock? What are analysts' forecasts for Merck & Co. stock? What is the future of Merck & Co. stock? We forecast Merck & Co. stock performance using neural networks based on historical data on Merck & Co. stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Merck & Co. stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Merck & Co. shares. This happens once a day.


Historical and forecast chart of Merck & Co. stock

The chart below shows the historical price of Merck & Co. stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Merck & Co. stock price can be found in the table below.

Long-term forecasts by years.

Unlocking the Secrets Behind MRK Stock Forecast: What You Need to Know

Trend: Bullish
May 29, 2024

As investors constantly search for the next big opportunity, understanding the drivers behind Merck & Co.'s (MRK) stock performance becomes crucial. In the rapidly evolving pharmaceutical landscape, MRK's stock forecast hinges on a trio of powerful factors poised to shape its trajectory. Topping this list is the Keytruda Franchise, MRK's crown jewel, which has surged past competitors to become a leading revenue powerhouse. Thanks to its protected status until 2028, Keytruda's continued dominance, particularly in immunotherapy for early-stage indications, signals a bullish outlook for MRK stock.

Gauging the Growth and Stability of MRK

Vital to MRK's stock price prediction is its Growth Outlook. With a diversified business model and investments in high-impact sectors like oncology, MRK is not just surviving; it's thriving. These strategic moves, coupled with a keen focus on developing markets, position MRK for sustained growth. These elements are instrumental for any analyst aiming to make accurate MRK stock price targets.

Moreover, the Financial Strength of Merck cannot be overlooked. Sporting an impressive A+ financial rating, MRK has demonstrated its ability to not only weather storms but to sail through them with confidence. This financial robustness makes MRK a compelling option for those pondering, "Is MRL a good stock to buy?"

In summary, wielding these insights into MRK's Keytruda franchise, growth outlook, and financial strength allows investors and analysts alike to navigate the MRK stock forecast with greater precision, unveiling opportunities to buy or sell Merck & Co. stock effectively.

  • Keytruda Franchise's dominance and patent protection
  • Well-balanced growth outlook in oncology and emerging markets
  • A+ financial strength supporting investments and stability

These guiding lights could be the beacon for making the most accurate MRK stock price predictions, potentially making MRK stock a highlight in any investment portfolio. Review the original Analysis

About author

Merck's Stock Surge: Riding the Wave of Keytruda and Gardasil Sales

Trend: Bullish
May 10, 2024

When peering into the future of Merck & Co. (NYSE: MRK) stock rates, a blend of innovation and sales growth emerges as the primary catalysts. Leading the charge, Keytruda, Merck's flagship oncology product, continues to dominate the market with its expanding indications and soaring demand, especially in the lucrative markets of the USA and Europe. This has significantly boosted the MRK stock forecast, with analysts keenly observing Keytruda's growth trajectory as a vital marker for potential stock price movements.

The Vaccine Vanguard: A Closer Look at Gardasil's Impact

Parallel to Keytruda's success, Gardasil and Gardasil 9 vaccines prop up Merck's financial fortitude, offering protection against various strains of the human papillomavirus (HPV). The increased focus on HPV immunization programs worldwide has catapulted the demand for these vaccines, turning them into another critical factor for analysts predicting the MRK stock price trend. The efficacy and growing demand of Gardasil underscore its role in shaping Merck's stock rate.

As we synthesize this data to forecast MRK stock price targets, the importance of monitoring the product development pipeline cannot be overstated. The evolution of experimental drugs and vaccines, alongside the approval of promising candidates, could further tilt the scales in favor of MRK stock price prediction. However, the looming specter of financial risks and competition, particularly from generic versions of Januvia and Janumet in the European Union, adds a layer of complexity for those debating whether MRK is a good stock to buy.

In essence, by meticulously analyzing the interplay between Keytruda and Gardasil sales growth, product pipeline evolution, and the overarching market dynamics, analysts are better positioned to make accurate MRK stock forecasts. These factors collectively wield the power to influence Merck & Co.'s stock fate in the near future, guiding investors in their decision-making process on whether to buy or sell Merck & Co. stock.

Review the original Analysis
About author

Unveiling the Future of MRK Stocks: A Financial Flight or Plunge?

Trend: Bullish
May 06, 2024

As the financial market watches, MRK stocks stand at a crucial juncture, poised for fluctuations influenced by key developments within Merck & Co. Analysts keen on providing accurate MRK stock forecasts are closely examining certain critical factors expected to shape the stock rates in the near future. Paramount among these are the company's commendable Q1 FY2024 financial performance, notable sales growth, and groundbreaking product developments in the pipeline.

Decoding the Future: MRK Stock Buy or Sell?

The remarkable 9% YoY growth in worldwide sales, fueled by pharmaceutical giants KEYTRUDA and GARDASIL/GARDASIL 9, not only signifies robust financial health but also solidifies investor confidence. Such growth is a beacon for predicting upward movements in MRK stock prices, making "Is MRK a good stock to buy?" one of the most pertinent questions among investors. Additionally, the potential approval of V116, a new pneumonia vaccine, and positive outcomes from critical trials, including a Keytruda combination for advanced stomach or esophageal cancer, brightly spotlight Merck's innovative trajectory. These developments are anticipated to burgeon sales further, enacting a positive ripple through MRK stock price predictions.

For analysts aiming to forecast the mercurial shifts in MRK company's stock price with precision, focusing on the interplay of its financial performance, product pipeline, and associated growth prospects becomes imperative. The allure of MRK's attractive valuation, underscored by a significantly low PEG ratio and tantalizing projected EPS growth over the next five years, crafts a narrative of potential stock appreciation. The synthesis of these elements provides a structured framework for making informed determinations on whether MRK stocks are a buy or sell, thereby demystifying the Merck & Co. stock forecast.

  • Financial Performance and Sales Growth
  • New Product Developments and Pipeline
  • Valuation and Growth Prospects

In essence, the dynamic interplay of Merck's financial robustness, innovative pipeline, and investment attractiveness will be instrumental in guiding the MRK stock price target. For investors asking, "Buy or sell Merck & Co. stock?", the answer lies in closely monitoring these unfolding developments.

Review the original Analysis
About author

Merck & Co is an international pharmaceutical company. Develops, manufactures and distributes vaccines and medicines. Also publishes non-commercial medical journals, reference books. In all countries except the United States and Canada, the company’s products are sold under the Merck Sharp & Dohme brand.

The company operates in 120 countries: North America, Latin America, Europe, Africa, Asia and the Middle East. Merck & Co employs 76 thousand people. For 23 years, Fortune magazine has included the company in the Fortune Global 500 – the rating of the largest corporations in the world. In 2017, Merck was ranked 246th.

The history of the company began in 1668 when Jacob Merck bought a pharmacy in Germany. 150 years later, Jacob’s great-grandson took over the family business and began mass production of drugs. At the beginning of the 20th century, Merck & Co was considered the largest producer of alkaloids: morphine, codeine and cocaine.

Official site of the company

Merck & Co. daily forecast for a month

Date Target Pes. Opt. Vol., %
Jun 01 127.39 126.40 128.10 1.35
Jun 02 127.94 127.46 128.53 0.83
Jun 03 128.30 127.74 128.72 0.76
Jun 04 127.09 126.52 127.76 0.98
Jun 05 126.93 126.48 127.46 0.77
Jun 06 128.05 127.54 128.77 0.96
Jun 07 127.68 127.36 128.09 0.57
Jun 08 127.36 126.46 128.38 1.52
Jun 09 127.50 126.59 128.35 1.39
Jun 10 126.57 125.75 127.23 1.18
Jun 11 126.07 125.30 126.58 1.03
Jun 12 126.34 125.99 127.27 1.01
Jun 13 127.57 126.96 128.44 1.17
Jun 14 128.73 128.10 129.10 0.78
Jun 15 130.02 129.52 130.42 0.69
Jun 16 130.77 129.78 131.11 1.03
Jun 17 130.94 130.29 131.94 1.27
Jun 18 130.47 129.94 130.80 0.66
Jun 19 130.18 129.17 131.13 1.52
Jun 20 130.43 129.79 130.78 0.76
Jun 21 129.79 128.81 130.67 1.45
Jun 22 130.40 129.36 131.03 1.29
Jun 23 131.60 131.27 132.13 0.65
Jun 24 131.63 131.27 132.25 0.74
Jun 25 131.71 131.34 132.63 0.98
Jun 26 131.87 131.59 132.38 0.60
Jun 27 131.01 130.13 131.85 1.32
Jun 28 131.35 130.88 132.14 0.96
Jun 29 131.73 131.29 132.53 0.94
Jun 30 132.28 131.29 133.33 1.55

Merck & Co. Daily Price Targets


Merck & Co. Stock Forecast 06-01-2024.

Forecast target price for 06-01-2024: $127.39.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 1.333%.
Pessimistic target level: 126.40
Optimistic target level: 128.10

Merck & Co. Stock Forecast 06-02-2024.

Forecast target price for 06-02-2024: $127.94.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 0.826%.
Pessimistic target level: 127.46
Optimistic target level: 128.53

Merck & Co. Stock Forecast 06-03-2024.

Forecast target price for 06-03-2024: $128.30.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 0.757%.
Pessimistic target level: 127.74
Optimistic target level: 128.72

Merck & Co. Stock Forecast 06-04-2024.

Forecast target price for 06-04-2024: $127.09.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 0.974%.
Pessimistic target level: 126.52
Optimistic target level: 127.76

Merck & Co. Stock Forecast 06-05-2024.

Forecast target price for 06-05-2024: $126.93.
Negative dynamics for Merck & Co. shares will prevail with possible volatility of 0.767%.
Pessimistic target level: 126.48
Optimistic target level: 127.46

Merck & Co. Stock Forecast 06-06-2024.

Forecast target price for 06-06-2024: $128.05.
Positive dynamics for Merck & Co. shares will prevail with possible volatility of 0.954%.
Pessimistic target level: 127.54
Optimistic target level: 128.77

MRK (MRK) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jun. 126.66 122.91 129.85 5.35
Jul. 129.75 127.88 133.33 4.09
Aug. 128.86 125.82 130.31 3.44
Sep. 125.31 122.55 126.76 3.32
Oct. 122.40 119.81 125.19 4.30
Nov. 126.56 124.39 127.62 2.54
Dec. 126.36 123.02 130.05 5.40

Merck & Co. forecast for this year


Merck & Co. Stock Prediction for Jun 2024

An uptrend is forecast for this month with an optimal target price of $126.655. Pessimistic: $122.91. Optimistic: $129.85


Merck & Co. Stock Prediction for Jul 2024

An uptrend is forecast for this month with an optimal target price of $129.746. Pessimistic: $127.88. Optimistic: $133.33


Merck & Co. Stock Prediction for Aug 2024

An downtrend is forecast for this month with an optimal target price of $128.864. Pessimistic: $125.82. Optimistic: $130.31


Merck & Co. Stock Prediction for Sep 2024

An downtrend is forecast for this month with an optimal target price of $125.307. Pessimistic: $122.55. Optimistic: $126.76


Merck & Co. Stock Prediction for Oct 2024

An downtrend is forecast for this month with an optimal target price of $122.4. Pessimistic: $119.81. Optimistic: $125.19


Merck & Co. Stock Prediction for Nov 2024

An uptrend is forecast for this month with an optimal target price of $126.561. Pessimistic: $124.39. Optimistic: $127.62


Merck & Co. Stock Prediction for Dec 2024

An downtrend is forecast for this month with an optimal target price of $126.359. Pessimistic: $123.02. Optimistic: $130.05



Merck & Co. (MRK) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 126.71 123.17 128.34 4.03
Mar 124.48 123.19 126.67 2.75
Mar 123.74 121.95 126.95 3.94
Apr 124.78 123.23 126.17 2.33
May 123.63 121.20 126.74 4.37
Jun 121.16 119.02 124.11 4.10
Jul 119.65 117.21 120.71 2.89
Aug 122.67 120.85 124.93 3.26
Sep 125.66 123.50 127.07 2.81
Oct 130.13 126.44 131.38 3.76
Nov 134.19 131.19 137.79 4.79
Dec 138.86 136.98 142.14 3.63

Merck & Co. (MRK) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 139.75 137.07 144.00 4.81
Mar 142.10 140.79 145.68 3.36
Mar 143.64 142.31 145.07 1.90
Apr 146.28 143.88 149.50 3.76
May 151.37 148.34 153.49 3.35
Jun 153.61 152.13 158.34 3.92
Jul 151.95 148.06 156.21 5.21
Aug 151.53 147.77 153.89 3.98
Sep 145.83 143.67 150.03 4.24
Oct 145.59 143.73 147.11 2.30
Nov 141.81 138.24 145.38 4.92
Dec 140.73 137.47 145.01 5.20

Merck & Co. (MRK) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 140.45 136.29 141.85 3.92
Mar 139.94 138.10 141.85 2.64
Mar 140.78 136.34 142.53 4.35
Apr 139.55 135.25 142.95 5.39
May 139.66 136.53 141.72 3.67
Jun 139.66 135.69 141.89 4.37
Jul 143.51 141.73 144.77 2.10
Aug 148.56 144.58 151.65 4.66
Sep 145.29 143.03 148.43 3.64
Oct 140.76 136.65 144.59 5.49
Nov 141.04 138.17 142.23 2.86
Dec 139.63 136.34 143.04 4.69

Merck & Co. (MRK) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 139.46 137.62 140.64 2.14
Mar 138.29 135.58 141.45 4.15
Mar 137.52 136.14 141.75 3.96
Apr 138.78 136.01 140.45 3.16
May 142.89 138.66 146.95 5.64
Jun 147.92 145.50 151.47 3.95
Jul 145.44 144.27 149.68 3.61
Aug 146.72 142.49 149.42 4.63
Sep 146.31 142.79 150.69 5.24
Oct 147.94 143.98 151.61 5.04
Nov 150.78 148.61 155.43 4.38
Dec 149.82 145.92 151.50 3.68

Merck & Co. information and performance

Merck & Co. Address

2000 GALLOPING HILL ROAD, KENILWORTH, NJ, US

Market Capitalization: 319 362 007 000 $

Market capitalization of the Merck & Co., Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of MRK shares in the company outstanding by the market price of one share.

EBITDA: 21 211 001 000 $

EBITDA of Merck & Co. is earnings before interest, income tax and depreciation of assets.

PE Ratio: 143.28

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 0.101

Price/earnings to growth

DPS: 2.96

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.0238

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 0.88

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.685
Quarterly Revenue Growth YOY: 0.089
Trailing PE: 143.28

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 14.68

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 5.76

Enterprise Value (EV) /Revenue

EV To EBITDA: 50.16

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 2532810000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Merck & Co. (MRK) stock dividend

Merck & Co. last paid dividends on 03/14/2024. The next scheduled payment will be on 04/05/2024. The amount of dividends is $2.96 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.




Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.